Skip to main content

Generic Wegovy Availability

Last updated on Aug 10, 2022.

Wegovy is a brand name of semaglutide, approved by the FDA in the following formulation(s):

WEGOVY (semaglutide - solution;subcutaneous)

  • Manufacturer: NOVO
    Approval date: June 4, 2021
    Strength(s): 0.25MG/0.5ML (0.25MG/0.5ML) [RLD], 0.5MG/0.5ML (0.5MG/0.5ML) [RLD], 1MG/0.5ML (1MG/0.5ML) [RLD], 1.7MG/0.75ML (1.7MG/0.75ML) [RLD], 2.4MG/0.75ML (2.4MG/0.75ML) [RLD]

Has a generic version of Wegovy been approved?

No. There is currently no therapeutically equivalent version of Wegovy available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Wegovy. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,888,605

    Patent expiration dates:

    • August 24, 2038
      ✓ 
      Patent use: METHOD FOR WEIGHT MANAGEMENT
      ✓ 
      Drug product
  • Patent 11,318,191

    Patent expiration dates:

    • February 17, 2041
      ✓ 
      Patent use: METHOD FOR WEIGHT MANAGEMENT
      ✓ 
      Drug product
  • Acylated GLP-1 compounds
    Patent 8,129,343
    Issued: March 6, 2012
    Inventor(s): Lau; Jesper & Bloch; Paw & Hansen; Thomas Kruse
    Assignee(s): Novo Nordisk A/S

    Protracted GLP-1 compounds and therapeutic uses thereof.

    Patent expiration dates:

    • December 5, 2031
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Acylated GLP-1 compounds
    Patent 8,536,122
    Issued: September 17, 2013
    Assignee(s): Novo Nordisk A/S

    Protracted GLP-1 compounds and therapeutic uses thereof.

    Patent expiration dates:

    • March 20, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Use of long-acting GLP-1 peptides
    Patent 9,764,003
    Issued: September 19, 2017
    Assignee(s): Novo Nordisk A/S

    The invention relates to use of long-acting GLP-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.

    Patent expiration dates:

    • June 21, 2033
      ✓ 
      Patent use: METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • December 5, 2022 - NEW CHEMICAL ENTITY
    • June 4, 2024 - NEW PRODUCT

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.